SINGAPORE (May 15): Net profit of catalist-listed pharmaceutical distributor Hyphens Pharma soared 48.6% to $2.1 million in 1Q20 ended March, from the $1.4 million logged a year ago.

On a fully diluted basis, this translates to earnings per share (EPS) of 71 cents, from 48 cents before. At this level, Hyphens Pharma’s net asset value was 15.26 cents a share, against 14.67 cents as at Dec 31.

The board says it will reclassify its proposed final dividend announced for FY19, as an interim dividend following a delay in payout due to Covid-19. Shareholders can expect to receive a payout of 1 cent a share on Jun 8, the company said in a regulatory filing on May 11.

The increased profits come on the back of growth in sales across the company’s three business segments of: specialty pharma principals (+11.2%), proprietary brands (+35.9%) and medical hypermart and digital (+17.0%).

Hyphens Pharma’s specialty pharma principals segment sees the company selling and marketing specialised pharmaceutical brands such as namesake products from Guerbet and Bausch+Lomb. 

Have a premium account? Sign in to continue reading.

Unlimited access to all stories from $4.99/month*

The latest reporting and analysis from business and investments to news and views on social issues.

Bonus:

  • Simultaneous logins across all devices
  • Instant access to past digital issues
  • Unlimited access to The Edge Malaysia
  • *For annual subscription plan only. T&Cs apply

SUBSCRIBE NOW